The identification of the active, downstream NF-κB transcription factors co-opted in DLBCL subtypes and the elucidation of their transcriptional programs could guide the development of drugs that specifically inhibit oncogenic NF-κB target genes or pathways, with more limited toxicity. This evidence concerns the gene NFKB1 and diffuse large B-cell lymphoma.